Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reddy

Showing results (781-790 of 796) with videos related to

Pageof 80
Sort By:
Journal of Radiosurgery and SBRT|July 7, 2023
Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcomaEashwar Somasundaram, Timothy D Smile, Ahmed Halima, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2018
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution AnalysisJimmy J Caudell, Matthew C Ward, Nadeem Riaz, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2017
Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI CollaborativeMatthew C Ward, Nadeem Riaz, Jimmy J Caudell, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2017
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck CancerJohn A Vargo, Matthew C Ward, Jimmy J Caudell, et al.
Neurology|September 16, 2011
GFAP mutations, age at onset, and clinical subtypes in Alexander diseaseM Prust, J Wang, H Morizono, et al.
The Journal of Experimental Medicine|June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trialMatthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Pageof 80

Showing results (781-790 of 796) with videos related to

Sort By:
Pageof 80
Journal of Radiosurgery and SBRT|July 7, 2023
Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcomaEashwar Somasundaram, Timothy D Smile, Ahmed Halima, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2018
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution AnalysisJimmy J Caudell, Matthew C Ward, Nadeem Riaz, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2017
Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI CollaborativeMatthew C Ward, Nadeem Riaz, Jimmy J Caudell, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2017
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck CancerJohn A Vargo, Matthew C Ward, Jimmy J Caudell, et al.
Neurology|September 16, 2011
GFAP mutations, age at onset, and clinical subtypes in Alexander diseaseM Prust, J Wang, H Morizono, et al.
The Journal of Experimental Medicine|June 20, 2020
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trialMatthew J Frank, Michael S Khodadoust, Debra K Czerwinski, et al.
Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Pageof 80